{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe+device",
    "query": {
      "intervention": "Syringe device"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1158,
    "total_pages": 116,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe+device&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T06:03:10.589Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01833754",
      "title": "Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Romosozumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-04-22",
      "completion_date": "2014-02-19",
      "has_results": true,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 5,
      "location_summary": "Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Orangeburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01833754"
    },
    {
      "nct_id": "NCT04134728",
      "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165 (Otilimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sarilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to GSK3196165/ Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "csDMARDs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2019-10-31",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 46,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134728"
    },
    {
      "nct_id": "NCT03589885",
      "title": "Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo 2 mL auto-injector",
          "type": "DRUG"
        },
        {
          "name": "Placebo 1 mL prefilled syringe",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 2 mL auto-injector",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 1 mL prefilled syringe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2018-12-19",
      "completion_date": "2020-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Saint Joseph",
          "state": "Missouri"
        },
        {
          "city": "Verona",
          "state": "New Jersey"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03589885"
    },
    {
      "nct_id": "NCT04525898",
      "title": "Intraoperative Methadone for Postoperative Pain Control After Thoracic Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Methadone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-10-09",
      "completion_date": "2021-02-01",
      "has_results": false,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04525898"
    },
    {
      "nct_id": "NCT05278858",
      "title": "Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "MedJet Device with intralesional triamcinolone",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 3,
      "start_date": "2022-03-24",
      "completion_date": "2023-06-06",
      "has_results": true,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05278858"
    },
    {
      "nct_id": "NCT06171555",
      "title": "Efficacy of CTM for Tennis ELbow",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tennis Elbow",
        "Lateral Epicondylitis \\(Tennis Elbow\\)",
        "Lateral Elbow Tendinopathy"
      ],
      "interventions": [
        {
          "name": "CTM",
          "type": "DEVICE"
        },
        {
          "name": "Celestone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Indiana Hand to Shoulder Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2023-01-26",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171555"
    },
    {
      "nct_id": "NCT01230684",
      "title": "Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Endograft Implantation to Repair Abdominal Aortic Aneurysm"
      ],
      "interventions": [
        {
          "name": "Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2010-12",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01230684"
    },
    {
      "nct_id": "NCT03559517",
      "title": "Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Ontamalimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-08-29",
      "completion_date": "2020-10-08",
      "has_results": true,
      "last_update_posted_date": "2021-04-29",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lancaster, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03559517"
    },
    {
      "nct_id": "NCT01875991",
      "title": "Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Etanercept via Autoinjector A",
          "type": "DRUG"
        },
        {
          "name": "Etanercept via Autoinjector B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2013-06-05",
      "completion_date": "2014-03-04",
      "has_results": true,
      "last_update_posted_date": "2018-09-04",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 28,
      "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875991"
    },
    {
      "nct_id": "NCT03554317",
      "title": "COMbination of Bipolar Androgen Therapy and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer",
        "Metastatic Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2018-09-05",
      "completion_date": "2023-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-09-05T06:03:10.589Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03554317"
    }
  ]
}